



1st Annual

HEART iN DIABETES

Where the Heart, Kidney and Diabetes Meet in Clinical Practice

July 14 – 16, 2017
Sheraton Downtown
Philadelphia, PA



www.HEARTiNDIABETES.com

Jointly Provided By:  MEEF  PESI

Administered By:  TMIOA



Dear Friends & Colleagues,

We would like to invite you to join us for the 1st Annual Heart in Diabetes Medical Conference. The Heart in Diabetes will take place on July 14-16, 2017 at the Sheraton Philadelphia Downtown Hotel.

This brand-new CME program is a unique medical meeting, bringing together world-renowned clinical leaders in Diabetes and Cardiovascular Disease. Recent trials have demonstrated a cardiovascular benefit from antihyperglycemic agents in people with diabetes. However, among experts, there is a gap in understanding the implications of these new developments and their role in managing these patients.

The meeting provides a platform to address the clinical science of the Heart in Diabetes by providing state-of-the-art information and highlighting its implications on practice while evaluating it from the cardiology, endocrine/diabetes, and kidney points of view. Topics include: Lipids, Glucose, ACS, CHF, Atherosclerosis, Vascular, the Kidney, Coagulation, Arrhythmia, and other related conditions. The meeting will promote discussion and interaction among the various specialists in how they develop their respective approaches to the management and prevention of Heart Disease in Diabetes.

If you are a Cardiologist, Endocrinologist, Nephrologist, Diabetologist, Lipidologist, Internist, or simply a Clinician with an interest in the Heart in Diabetes - this meeting is for you! We personally invite you to join us in this exciting endeavor.

Please register today! Do not hesitate to contact us with any questions.

We look forward to having you join us for this exciting conference in Philadelphia.



Yehuda Handelsman, MD, FNLA, FACP, MACE *Chair*



Mikhail N. Kosiborod, MD, FACC, FAHA *Chair*

HiD SCIENTIFIC COMMITTEE

Yehuda Handelsman, MD *Chair*
Tarzana, CA

Mikhail Kosiborod, MD *Chair*
Kansas City, Missouri

Deepak Bhatt, MD
Boston, MA

Zachary Bloomgarden, MD
New York, NY

Matt Budoff, MD
Los Angeles, CA

David Cherney, PhD, MD
Toronto, Canada

Robert Chilton, DO
San Antonio, Texas

Ralph DeFronzo, MD
San Antonio, Texas

Daniel Einhorn, MD
San Diego, California

Sergio Fazio, MD, PhD
Portland, Oregon

Vivian Fonseca, MD
New Orleans, Louisiana

Alan Garber, MD, PHD
Houston, TX

Peter Grant, MD
Leeds, United Kingdom

George Grunberger, MD
Bloomfield Hills, Michigan

Mansoor Husain, MD
Toronto, Canada

Silvio Inzucchi, MD
New Haven, Connecticut

Ray Kausik, PHD
London, United Kingdom

Larry Leiter, MDCM,
Toronto, Canada

Norman Lepor, MD
Los Angeles, California


Derek LeRoith, MD, PhD
New York, New York

Christos Mantzoros, MD
Boston, Massachusetts

Nikolaus Marx, MD
Aachen, Germany

Benjamin Scirica, MD
Boston, MA

Matthew Weir, MD
Maryland, Baltimore



PROGRAM DESCRIPTION:

This CME program is a unique medical conference bringing together world renowned clinical leaders in diabetes and cardiovascular disease. The program is designed to evaluate the state of the art clinical data focusing on the management heart and kidney in diabetes. The goal is to align cardiologists, endocrinologists/diabetologists, iridologists, and nephrologists in their understanding and development of appropriate comprehensive clinical management plans for very high risk patients.

PROGRAM OBJECTIVES: Upon completion of this meeting, participants should be able to:

- Describe the relationship between diabetes, obesity, and the heart
- Explain the roles of diabetes and obesity in the development of kidney disease, retinopathy, CVD, and arrhythmia
- Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia
- Understand cardiovascular outcomes trials (CVOT) and the role of real-life big data in assessing management
- Evaluate antihyperglycemic CVOT results, specifically the use of SGLT2 inhibitors and GLP1 RAs to reduce cardiovascular morbidity and mortality in patients with T2D
- Understand CHF in diabetes to implement best practices for the management of CHF
- Evaluate the extent of vascular disease in diabetes and cardiometabolic syndrome
- Explain the role of lipids, in particular LDL-C and non-HDL-C, in the development of atherosclerosis
- Describe the role of PCSK9 in lipid homeostasis and the impact of monoclonal antibody therapy with PCSK9 inhibitors on cardiovascular disease
- Understand risk categories and determine appropriate targets of lipid-lowering therapy as outlined in the AACE 2017 Dyslipidemia Management Clinical Guidelines
- Appropriately diagnose and treat hypercoagulation and thrombosis as consequences of insulin resistance, inflammation, and diabetes
- Address the proper anticoagulation agents in the management of the high-risk patient
- Understand the combination treatments of CHF, hypertension, and lipid disorders
- Discuss the role of combination therapy in the management of obesity and diabetes with a focus on incretin- and SGLT2 inhibitor–based treatment

TARGET AUDIENCE

Cardiologists, endocrinologists, nephrologists, diabetologists, lipidologists, internists, family clinicians, and other professionals who are interested in the Heart in Diabetes.

**The HiD Scientific Committee Gratefully Acknowledges the
Unrestricted Educational Grant of**

**ASTRAZENECA • BI/LILLY • MERCK
NOVO NORDISK • PFIZER MERCK ALLIANCE**



FRIDAY, JULY 14, 2017

11:00am - 3:00pm

Pre Registration

2:00 pm - 3:00pm

WELCOME EXHIBITORS AT EXHIBIT HALL

3:00pm

Welcome & Introduction

Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD

SESSION 1

PREVALENCE AND PATHOPHYSIOLOGY OF CVD AND DIABETES

Chair: Deepak Bhatt, MD MPH • Silvio E. Inzucchi, MD

3:10pm

Epidemiology of CVD in Diabetes and Metabolic Syndrome

Nathan D. Wong, PhD

3:35pm

Insulin Resistance, CVD, and T2D - The Missing Link

Ralph A. DeFronzo, MD

4:05pm

The Cardio-Renal Syndrome

Peter A. McCullough, MD, MPH

4:30pm

From Microvascular to Macrovascular, is it Spectrum of the Same Disease?

Kausik Ray, MD, MBChBFRCP, MPhil

4:55pm - 5:10pm

Panel Discussion: Is the Pathophysiology of CVD Different in People with Diabetes

5:10pm - 5:40pm

REFRESHMENT BREAK AT EXHIBIT HALL

SESSION 2

THE KIDNEY IN DIABETES

Chair: Ralph A. DeFronzo, MD • Nikolaus Marx, MD

5:40pm

The Impact of Kidney Disease on CHF in Diabetes

Jeffrey Testani, MD, MTR

6:05pm

The Role of RAAS-i in the Management and Prevention CV, CHF & Renal Complications of T2D

Akshay S. Desai, MD, MPH

6:30pm

Predicting, Managing and Preventing CKD & CVD in DM— Traditional & Contemporary Approach

Matthew R. Weir, MD

6:55pm

Panel Discussion: Cardio Renal Syndrome Myth or Reality

7:10pm - 8:15pm

WELCOME RECEPTION AT EXHIBIT HALL

SATURDAY, JULY 15, 2017

7:00am - 8:00am

REGISTRATION • CONTINENTAL BREAKFAST

SESSION 3

THE ROLE OF T2D MEDICATION IN TRANSFORMING CVD RISK MANAGEMENT IN DM

Chair: Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD

8:00am KEY NOTE

CV Outcomes and Safety of oral glucose lowering agents: Implication for Clinical Practice

George Bakris, MD

8:30am

Pioglitazone: Due for Resurrection . . . or Reincarnation?

Silvio E. Inzucchi, MD

8:55am

Impact of SGLT2 Inhibition on Cardiovascular Events – An Update.

Nikolaus Marx, MD

9:20am

GLP-1RA Reduce Cardiovascular Events in High Risk Patients with T2D: Lessons from LEADER and SUSTAIN-6

Mansoor Husain, MD

9:45am

The Impact of Metformin, Cycloset, Precose, Insulin, and SU on CVD in DM

Lawrence Blonde, MD

10:10am - 10:45am

Panel Discussion: The Paradigm Shift on Managing People with Diabetes

Moderators: Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD

10:45am - 11:15am

REFRESHMENT BREAK AT EXHIBIT HALL

SESSION 4

THROMBOSIS AND DIABETES

Chair: Norman E. Lepor, MD • Matthew R. Weir, MD

11:15am

Hypercoagulation & Hyperglycemia partner in developing CVD in Diabetes

Peter J. Grant, MD, FmDSci

11:40am

Antithrombotic Therapy in Managing CVD in DM

Deepak Bhatt, MD, MPH

12:05pm - 12:20pm

Panel Discussion: Is There a Role for Antithrombotic Agents in Primary Prevention of CV Events in Diabetes

12:40pm - 1:30pm

PRODUCT THEATER None CME Lunch will be Provided

Repatha® A Focus Clinical Review

Supported by: **Amgen**

Harold E. Bays, MD





SATURDAY, JULY 15, 2017 (cont.)

SESSION 5

ARRHYTHMIA, SUDDEN DEATH & HYPOGLYCEMIA IN DIABETES

Chair: Christos Mantzoros MD, DSc • Mansoor Husain, MD

1:45pm
2:10pm
2:35pm
3:00pm - 3:15pm
3:15pm - 3:45pm

The Metabolic & CV Risk Factors Impact of Hypoglycemia
 Ventricular Tachycardia and Sudden Death in Diabetes
 The Role of Autonomic Neuropathy in Cardiovascular Events and Mortality in Diabetes
Panel Discussion: Arrhythmia - Hypoglycemia what gives?
REFRESHMENT BREAK

Stephen N. Davis, MD
 Valentina Kutylifa, MD, Msc, PhD
 Aaron Vinik, MD, PhD

SESSION 6

MANAGING OF ACUTE CORONARY SYNDROME IN DIABETES

Chair: Robert Chilton, DO • Alan J. Garber, MD PhD

3:45pm
4:10pm
4:35pm - 4:50pm

The Preferred Procedures in People with ACS & Diabetes
 The Role of Medications in Controlling Hyperglycemia in ACS
Panel Discussion: Should the Management of ACS be Different in People with DM?

Michael Farkouh, MD
 Norman E. Lepor, MD

SESSION 7

CONGESTIVE HEART FAILURE IN DIABETES

Chair: Matthew J. Budoff, MD • Kausik Ray, MD, MBChB, MPhil

4:50pm
5:10pm
5:30pm
5:50pm
6:10pm - 6:30pm

The Epidemiology & Different phenotypes of Heart failure- HFpEF vs HFrEF
 Heart Failure with Preserved Ejection Fraction
 Heart Failure with Reduced Ejection Fraction
 The Role of the Diabetologist in the Management of CHF in Diabetes
Panel Discussion: Treatment Intervention of CHF – Can Sudden Death be Prevented

Mikhail N. Kosiborod, MD
 Eldrin F. Lewis, MD, MPH
 Kenneth B. Margulies, MD
 Vivian A. Fonseca, MD

6:45pm - 9:00pm

CME Dinner Symposium The Real Deal: Translating Cardiovascular Outcomes Data into Best Practices in Type 2 Diabetes Management



Supported by an Educational Grant from AstraZeneca

7:00pm Introduction
 Yehuda Handelsman, MD
7:10pm Grading the Evidence: Understanding the Strengths and Limitations of RCTs and Big Data Studies
 Zachary T. Bloomgarden, MD
7:35pm Traditional Cardiovascular Outcomes in Type 2 Diabetes: What Should We Know?
 Ralph A. DeFronzo, MD

8:00pm Big Data Studies: What Should We Know?
 Mikhail N. Kosiborod MD
8:25pm Panel Discussion and Q&A: Randomized Trials vs Real Life Data - Can They Coexist?
Panel: Zachary T. Bloomgarden, MD • Robert Chilton, DO
 Ralph A. DeFronzo, MD • Peter Grant, MD
 Mikhail N. Kosiborod, MD
 Yehuda Handelsman, MD
Moderator: Yehuda Handelsman, MD
8:50pm-9:00pm Concluding Remarks

SUNDAY, JULY 16, 2017

7:00am - 8:00am

CONTINENTAL BREAKFAST

SESSION 8

CVD RISK PREDICTION IN PEOPLE WITH DIABETES - DEBATE

Chair: Zachary T. Bloomgarden, MD • Sergio Fazio, MD, PhD

8:00am
8:30am
9:00am- 9:15am

Biomarkers are Better in Predicting CV Risk in Diabetes
 Imaging is Better in Predicting CV Risk in Diabetes
Panel Discussion: What is the Best CV Risk Calculator in People with Diabetes

Michael H. Davidson, MD
 Matthew J. Budoff, MD

SESSION 9

DIABETES, DYSLIPIDEMIA & CARDIOVASCULAR DISEASE

Chair: Peter J. Grant, MD, FmdSci • Vivian A. Fonseca, MD

9:15am
9:40am
10:00am - 10:30am
10:30am
10:55am
11:20am
11:45am
12:15pm

Diabetes- Assessing CV Risk and Approach to Therapy
 AACE 2017 Lipid & CV Prevention Guidelines - The Extreme Risk Patient
REFRESHMENT BREAK
 The Spectrum of Dyslipidemia in Diabetes and Residual Risk After LDL Control.
 The Role of LDL-C in Diabetes & Cardiometabolic Conditions - Implication of the FOURIER Outcome trial
 CVD and its management in T1D
Panel Discussion: Lipids & Beyond- Reducing CV Risk in People with Diabetes.
 Adjourn

Christie M. Ballantyne, MD
 Yehuda Handelsman, MD
 Sergio Fazio, MD, PhD
 Henry N. Ginsberg, MD
 Richard E. Pratley, MD

FACULTY 2017



Yehuda Handelsman, MD
FNLA, FACP, MACE, Chair
 Chair & Program Director, 14th Annual WCRDC
 Medical Director & Principal Investigator
 Metabolic Institute of America
 Chair & Founder, International Committee
 for Insulin Resistance
 Chair & Founder, International Lipid Forum
 Tarzana, California



Mikhail N. Kosiborod, MD,
FACC,FAHA, Chair
 Professor of Medicine,
 Saint Luke's Mid America Heart Institute
 University of Missouri-Kansas City
 Kansas City, Missouri



George Bakris, MD
 Professor of Medicine
 Section of Endocrinology, Diabetes, and Metabolism
 Committee on Molecular Metabolism and Nutrition
 Director, Comprehensive Hypertension Center
 Nephrology, University of Chicago Medical Center
 Chair, American Diabetes Association
 Principal Investigator, FIDELIO
 Chicago, Illinois



Christie M. Ballantyne, MD
 Professor of Medicine
 Vice Chair of Research for the
 Department of Medicine
 Chief, Section of Cardiovascular Research
 Chief, Section of Cardiology
 Department of Medicine
 Baylor College of Medicine
 Houston, Texas



Deepak L. Bhatt, MD, MPH
FACC,FAHA
 Executive Director of
 International Cardiovascular Programs
 Brigham and Women's Hospital
 Heart and Vascular Center
 Professor of Medicine
 Harvard Medical School
 Boston, Massachusetts



Zachary T. Bloomgarden, MD, MACE
 Clinical Professor of Medicine
 Mount Sinai School of Medicine
 Assistant Attending in Medicine
 Mount Sinai Hospital
 Consultant in Endocrinology Lawrence Hospital
 New York, New York



Matthew J. Budoff, MD
 Professor of Medicine
 David Geffen School of Medicine at UCLA
 Los Angeles, CA



Robert J. Chilton, DO, FACC
 Professor of Medicine
 Department of Medicine
 Division of Cardiology
 The University of Texas
 Health Science Center
 San Antonio, Texas



Michael Davidson, MD
FACC,FACP, FNLA
 Professor, Director of the Lipid Clinic
 The University of Chicago Pritzker
 School of Medicine
 Chicago, Illinois



Stephen N. Davis, MD, MBBS
 Theodore E. Woodward
 Professor of Medicine Professor of Physiology
 Chairman, Department of Medicine
 University of Maryland School of Medicine
 Vice President of Clinical Translational
 Science University of Maryland Baltimore
 Physician-in-Chief, University
 of Maryland Medical Center
 Baltimore, Maryland



Ralph A. DeFronzo, MD
 Professor of Medicine
 Chief, Diabetes Division
 University of Texas
 Health Science Center at San Antonio
 Director, Texas Diabetes Institute
 San Antonio, Texas



Akshay S. Desai, MD, MPH
 Director, Heart Failure Disease Management
 Cardiovascular Division Brigham
 and Women's Hospital
 Associate Professor
 of Medicine Harvard Medical School
 Boston, Massachusetts



Michael Farkouh, MD
 Peter Munk Chair
 Multinational Clinical Trials
 Toronto, Ontario, Canada



Sergio Fazio, MD, PhD
 The William and Sonja Connor
 Chair of Preventive Cardiology
 Professor of Medicine and Physiology
 & Pharmacology
 Director, Center for Preventive Cardiology
 Knight Cardiovascular Institute
 Oregon Health and Science University
 Portland, Oregon



Vivian A. Fonseca, MD
 Professor of Medicine and Pharmacology
 Tullis Tulane Alumni Chair in Diabetes
 Chief, Section of Endocrinology
 Tulane University Health Sciences Center
 New Orleans, Louisiana



Lawrence Blonde, MD
FACP, FACE
 Professor of Medicine
 Director of the Ochsner Diabetes Clinical Research
 Unit in the Department of Endocrinology,
 Diabetes and Metabolism,
 Associate Internal Medicine Residency Program
 Director at the Ochsner Medical Center in
 New Orleans, Louisiana



Peter J. Grant, MD, FMedSci
 Professor of Medicine and
 Honorary Consultant Physician,
 Leeds Acute Trust, LIGHT Laboratories
 University of Leeds
 Leeds, United Kingdom



Henry N. Ginsberg, MD
 Herbert & Florence Irving
 Professor of Medicine
 Director, Irving Institute for
 Clinical and Translational Research
 Columbia University
 New York City, New York



Mansoor Husain, MD
BSc, FRCPC
 Executive Director, Ted Rogers
 Centre for Heart Research
 Director, Toronto General Hospital
 Research Institute, University Health Network
 Professor, Department of Medicine
 University of Toronto
 Senior Scientist, Toronto General Hospital
 Research Institute, University Health Network
 Toronto, Canada



Silvio E. Inzucchi, MD
 Professor of Medicine, Endocrinology
 Clinical Director, Section of Endocrinology
 Director, Yale Diabetes Center
 Director, Endocrinology & Metabolism Fellowship
 Director, Yale Affiliated Hospitals Program
 New Haven, Connecticut



Valentina Kutlyifa, MD, PhD
 Valentina Kutlyifa, MD, PhD
 Associate Professor (Cardiology)
 University of Rochester Medical Center,
 Rochester, New York



Norman E. Lepor, MD, FACC
FAHA, FSCAI
 Clinical Professor of Medicine
 Geffen School of Medicine, UCLA
 Attending Cardiologist
 Cedars-Sinai Heart Institute
 Los Angeles, CA



Eldrin Foster Lewis, MD, MPH
 Associate Professor of Medicine
 Harvard Medical School
 Associate Physician
 Brigham and Women's Hospital
 Cardiology, Advanced Heart Failure and Transplant
 Boston, Massachusetts



Christos Mantzoros, MD, DSc
 Professor of Medicine
 Harvard Medical School
 Chief of Endocrinology, Diabetes,
 & Metabolism
 Editor-in-Chief, Metabolism
 Clinical and Experimental
 Boston, Massachusetts



Kenneth B. Margulies, MD
 Professor of Medicine and Physiology
 Research and Fellowship Director
 Heart Failure and Transplant Program
 Perelman School of Medicine
 University of Pennsylvania
 Philadelphia, Pennsylvania



Nikolaus Marx, MD
FESC, FAHA
 Professor of Medicine / Cardiology
 Head of Department of Internal Medicine I,
 Cardiology, Pneumology, Angiology
 and Intensive Care
 University Hospital Aachen
 Aachen, Germany



Peter A. McCullough, MD
 Vice Chief of Medicine,
 Baylor University Medical Center
 Dallas, Texas



Richard E. Pratley, MD
 Professor of Medicine
 Senior Investigator
 Translational Research Institute for
 Metabolism and Diabetes
 Florida Hospital, Wayne State University
 School of Medicine
 Orlando, Florida



Kausik Ray, MD
MBChBFRCP, MPHil
FACC, FESC, FAHA
 Professor of Public Health
 Consultant Cardiologist
 Imperial College London
 London, United Kingdom



Jeffrey Testani, MD, MTR
 Assistant Professor of Medicine
 (Cardiology)
 Director of Heart Failure Research
 Yale University School of Medicine
 New Haven, Connecticut



Aaron Vinik, MD, PhD
FCP, MACP, FACE
 Murray Walizer Endowed
 Chair for Diabetes Research
 Professor of Medicine/Pathology/Neurobiology
 Director of Research and Neuroendocrine Unit
 Norfolk, Virginia



Matthew R. Weir, MD
 Professor of Medicine
 Director of Nephrology
 Department of Medicine
 University of Maryland School of Medicine
 Baltimore, Maryland



Nathan D. Wong, PhD
FACC, FAHA
 Professor and Director
 Heart Disease Prevention Program
 University of California, Irvine
 Irvine, California



**Register online: www.heartindiabetes.com/registration
or email us: info@tmioa.com
To register by phone: 818-342-1889**

CANCELLATION POLICY: A \$50 cancellation fee will be charged for cancellation between May 15, 2017 and June 14, 2017. After June 14, 2017 there will be NO REFUND. We encourage participation by all individuals. If you have a disability, please notify us in writing of any special requirements to help us serve you better.

ACCREDITATION INFORMATION

You can earn up to 17 credits

CME Accreditation: This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI, Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI, Inc. is accredited by the ACCME to provide continuing medical education for physicians. **AMA PRA Designation Statement.**

The PESI, Inc. designated this live activity for a maximum of 17 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity **International CME** International Physicians are formally eligible for AMA PRA Category 1 Credit™. **Physician Assistants** AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME. **Nurses** For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

Pharmacists For the purpose of recertification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI, Inc. as approved ACCME provider. This course qualifies for 17 continuing education hours. **Registered Dietitians** For the purpose of recertification, the Commission on Dietetic Registration accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME.

Satisfactory completion for credits All attendees must have completed and turned in a course attendance/evaluation form prior to leaving the conference. Each session claimed for credit must be attended in its entirety. Each session claimed for credit must be attended in its entirety.

ACCOMMODATIONS

The 1st Annual Heart in Diabetes (HiD) CME conference will be held at the Sheraton Downtown Philadelphia Hotel 201 North 17th Street, Philadelphia, PA 19103 (215) 448-2000 www.sheratonphiladelphiadowntown.com

To reserve a room at the special rate of \$159 single/double a night for conference participants and their guests please go online : www.heartindiabetes.com/accomodations or call 1-800-325-3535 to make your individual reservation within the room block by providing the following information:

Event Name: 1st Annual Congress on Heart in Diabetes (HiD)

Reservation ID: MG10AA

Group rate is available until June 16, 2017 subject to availability

Rooms will be available on a first-come basis, and will be available until all are filled. Group room rates will be available three (3) days prior to and three (3) days after the event date. If you need special accommodations or if you have any questions about access to any of our activities, please contact the meeting organizers at 818 342 1889 or info@tmioa.com.

**The HiD Scientific Committee Gratefully Acknowledges the
Corporate Support of**

AMGEN • JANSSEN • SANOFI

The Metabolic Institute of America (TMIOA)

18372 Clark Street #212, Tarzana, CA 91356



1st Annual

HEART IN DIABETES

Where the Heart, Kidney and Diabetes Meet in Clinical Practice

NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS CA
PERMIT # 659

July 14 - 16, 2017 • Sheraton Downtown Philadelphia • 201 North 17th Street, Philadelphia, PA 19103

USE COUPON CODE **"BROCHURE"** AND SAVE 10% ON REGISTRATION

**Register online: www.heartindiabetes.com/registration
or email us: info@tmioa.com
To register by phone: **818-342-1889****

CANCELLATION POLICY: A \$50 cancellation fee will be charged for cancellation between May 15, 2017 and June 14, 2017. After June 14, 2017 there will be NO REFUND. We encourage participation by all individuals. If you have a disability, please notify us in writing of any special requirements to help us serve you better.

ENDORISING ORGANIZATIONS:

- American Association of Clinical Endocrinologists (AACE)
- American College of Endocrinology (ACE)
- American Society for Preventive Cardiology (ASPC)
- FH Foundation
- Medical Society of New Jersey
- National Lipid Association

MEDIA PARTNERS:

- Cardiology Today
- Endocrine Today
- JSCIMED Central
- Physician's Weekly

For Additional information on
REGISTRATION • ACCOMODATION • SUPPORT • EXHIBIT
818-342-1889 info@tmioa.com
www.heartindiabetes.com